NIHR Biomedical Research Centre, Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, UK.
NIHR Biomedical Research Centre, Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, UK; Institute for Life Sciences, University of Southampton, UK.
Curr Opin Pharmacol. 2018 Oct;42:16-21. doi: 10.1016/j.coph.2018.06.005. Epub 2018 Jul 8.
Mycobacterium tuberculosis (Mtb) kills more humans than any other infection and drug resistant strains are progressively emerging. Whilst the successful development of new agents for multi-drug resistant Mtb represents a major step forward, this progress must be balanced against recent disappointments in treatment-shortening trials. Consequently, there is a pressing need to strengthen the pipeline of drugs to treat tuberculosis (TB) and develop innovative therapeutic regimes. Approaches that bridge diverse disciplines are likely to be required to provide systems that address the limitations of current experimental models. Mtb is an obligate human pathogen that has undergone extensive co-evolution, resulting in a complex interplay between the host and pathogen. This chronic interaction involves multiple micro-environments, which may underlie some of the challenges in developing new drugs. The authors propose that advanced cell culture models of TB are likely to be an important addition to the experimental armamentarium in developing new approaches to TB, and here we review recent progress in this area and discuss the principal challenges.
结核分枝杆菌（Mtb）导致的人类死亡比其他任何感染都多，而且耐药菌株也在不断出现。虽然成功开发针对耐多药 Mtb 的新药物代表了向前迈出的重要一步，但必须平衡这一进展与治疗缩短试验中的最新失望。因此，迫切需要加强治疗结核病（TB）的药物库并开发创新的治疗方案。为了提供解决当前实验模型局限性的系统，可能需要结合不同学科的方法。Mtb 是一种专性人类病原体，经历了广泛的共同进化，导致宿主和病原体之间的复杂相互作用。这种慢性相互作用涉及多个微环境，这可能是开发新药的一些挑战的基础。作者提出，TB 的先进细胞培养模型很可能是开发 TB 新方法的实验工具包的重要补充，在此我们回顾该领域的最新进展，并讨论主要挑战。
